136 related articles for article (PubMed ID: 31376465)
1. Development of a safe and versatile suspension vehicle for pediatric use: Formulation development.
Alarie H; Roullin VG; Leclair G
Int J Pharm; 2019 Oct; 569():118552. PubMed ID: 31376465
[TBL] [Abstract][Full Text] [Related]
2. Extemporaneous benznidazole oral suspension prepared from commercially available tablets for treatment of Chagas disease in paediatric patients.
García MC; Manzo RH; Jimenez-Kairuz AF
Trop Med Int Health; 2015 Jul; 20(7):864-70. PubMed ID: 25784402
[TBL] [Abstract][Full Text] [Related]
3. Stability of refrigerated miglustat after preparation in InOrpha(®) flavored suspending excipient for compounding of oral solutions and suspensions.
Riahi S; Ambühl M; Stichler J; Bandilla D
Drug Des Devel Ther; 2015; 9():561-6. PubMed ID: 25632223
[TBL] [Abstract][Full Text] [Related]
4. Stability of an Alcohol-free, Dye-free Hydrocortisone (2 mg/mL) Compounded Oral Suspension.
Manchanda A; Laracy M; Savji T; Bogner RH
Int J Pharm Compd; 2018; 22(1):66-75. PubMed ID: 29385387
[TBL] [Abstract][Full Text] [Related]
5. Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt.
Graves R; Phan KV; Bostanian LA; Mandal TK; Pramar YV
Int J Pharm Compd; 2017; 21(4):334-338. PubMed ID: 28719376
[TBL] [Abstract][Full Text] [Related]
6. A novel oil-based suspension of a micro-environmental, pH-modifying solid dispersion for parenteral delivery: Formulation and stability evaluation.
Zhang S; Wan Q; Xu X; Xing Y; Ding J; Yang S; Sun W; Lu M; Pan B
Colloids Surf B Biointerfaces; 2019 Jul; 179():382-392. PubMed ID: 30999117
[TBL] [Abstract][Full Text] [Related]
7. Development of new ophthalmic suspension prednisolone acetate 1%.
Akram M; Shyum SB; Gauhar S
Pak J Pharm Sci; 2010 Apr; 23(2):149-54. PubMed ID: 20363691
[TBL] [Abstract][Full Text] [Related]
8. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4.
Polonini H; da Silva SL; Brandão MAF; Bauters T; De Moerloose B; Ferreira AO
Int J Pharm Compd; 2018; 22(6):516-526. PubMed ID: 30384353
[TBL] [Abstract][Full Text] [Related]
9. Stability and viscosity of a flavored omeprazole oral suspension for pediatric use.
Burnett JE; Balkin ER
Am J Health Syst Pharm; 2006 Nov; 63(22):2240-7. PubMed ID: 17090745
[TBL] [Abstract][Full Text] [Related]
10. Development of a topical suspension containing three active ingredients.
Chang HC; Li LC; Toongsuwan S; Stephens D; Liu RM; Plichta-Mahmoud H
Drug Dev Ind Pharm; 2002 Jan; 28(1):29-39. PubMed ID: 11858522
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date.
Peacock GF; Sauvageot J; Hill A; Killian A
Int J Pharm Compd; 2016; 20(1):81-5. PubMed ID: 27125058
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations.
Visser JC; Ten Seldam IEJ; van der Linden IJ; Hinrichs WLJ; Veenendaal RFH; Dijkers ECF; Woerdenbag HJ
Int J Pharm Compd; 2018; 22(3):247-251. PubMed ID: 29878892
[TBL] [Abstract][Full Text] [Related]
13. Stability and uniformity of extemporaneous preparations of voriconazole in two liquid suspension vehicles at two storage temperatures.
Nguyen KQ; Hawkins MG; Taylor IT; Wiebe VJ; Tell LA
Am J Vet Res; 2009 Jul; 70(7):908-14. PubMed ID: 19566477
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical suspensions of ursodeoxycholic acid for pediatric patients:
Boscolo O; Salvo L; Dobrecky C; Fissore EN; Buontempo F; Tripodi V; Lucangioli SE
Pharm Dev Technol; 2021 Jun; 26(5):599-609. PubMed ID: 33759695
[TBL] [Abstract][Full Text] [Related]
15. Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding.
Zhao F; Dave VS; Mar MZ; Perri JR
Int J Pharm Compd; 2018; 22(5):433-439. PubMed ID: 30384342
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel physico-chemically and microbiologically stable oral solution of flecainide for pediatrics.
Santoveña A; Charola I; Suárez-González J; Teigell-Pérez N; García-van Nood S; Soriano M; Fariña JB
Pharm Dev Technol; 2018 Dec; 23(10):978-985. PubMed ID: 27658320
[TBL] [Abstract][Full Text] [Related]
17. Development of a taste-masked oral suspension of clindamycin HCl using ion exchange resin Amberlite IRP 69 for use in pediatrics.
Alayoubi A; Daihom B; Adhikari H; Mishra S; Helms R; Almoazen H
Drug Dev Ind Pharm; 2016 Oct; 42(10):1579-89. PubMed ID: 26926148
[TBL] [Abstract][Full Text] [Related]
18. Formulation design of oral pediatric Acetazolamide suspension: dose uniformity and physico-chemical stability study.
Santoveña A; Suárez-González J; Martín-Rodríguez C; Fariña JB
Pharm Dev Technol; 2017 Mar; 22(2):191-197. PubMed ID: 27109383
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical and microbiological stability studies of extemporaneous antihypertensive pediatric suspensions for hospital use.
Mendes C; Costa AP; Oliveira PR; Tagliari MP; Silva MA
Pharm Dev Technol; 2013; 18(4):813-20. PubMed ID: 22670721
[TBL] [Abstract][Full Text] [Related]
20. Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide.
Santoveña A; Hernández-Paiz Z; Fariña JB
Int J Pharm; 2012 Feb; 423(2):360-4. PubMed ID: 22155411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
